People · Operator
Named in public records as an officer, director or promoter · active 2015–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adicet Bio, Inc. | — | Biotechnology | Series C | $116.8M | $3.3B | 2015 |
| Vaxin Inc. | — | Biotechnology | Series C | $50.0M | $1.7B | 2015 |
| Gensight Biologics S.A. | — | Biotechnology | Series B | $25.0M | $991.7M | 2015 |
| Kanyos Bio, Inc. | — | Biotechnology | Series A | $16.4M | $376.0M | 2015 |
Florent Gros at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Florent Gros on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Asish Xavier | 1 | 18 |
| Jack Nielsen | 1 | 13 |
| Jonathan Silverstein | 1 | 10 |
| Erez Chimovits | 1 | 7 |
| Thomas Woiwode | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Brian Hogan | 1 | 4 |
| Yair Schindel | 1 | 4 |
| Donald Santel | 1 | 4 |
| Nathan Hubbard | 1 | 3 |
| Marten Steen | 1 | 3 |
| Guido Magni | 1 | 3 |
| Jeffrey Hubbell | 1 | 2 |
| David Drutz | 1 | 2 |
| Aya Jakobovits | 1 | 2 |
| Bernard Gilly | 1 | 2 |
| Peter Goodfellow | 1 | 2 |
| Harry Welten | 1 | 1 |
| Andre Mueller | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.